Experienced in Ewing Sarcoma

Judith R. Kroep

Lumc
Leiden, ZH, NL 
Experienced in Ewing Sarcoma
Lumc
Leiden, ZH, NL 
OverviewLocationsClinical Research

Overview

Judith Kroep practices in Leiden, Netherlands. Ms. Kroep is rated as an Experienced expert by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Breast Cancer, Ovarian Cancer, Menopause, Mastectomy, and Synovectomy.

Her clinical research consists of co-authoring 181 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of Ewing Sarcoma.

Gender
Female

Locations

LUMC
Leiden, ZH, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Other
Study Phase: Not Applicable
Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Patients with Personalized Therapy (SUBITO) - an International Randomized Phase III Trial
Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Patients with Personalized Therapy (SUBITO) - an International Randomized Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 20, 2024
Intervention Type: Drug
Study Drugs: ddAC-CP-Olaparib, ddAC-mini CTC
Study Phase: Phase 3
Biomarker Discovery Randomized Phase IIb Trial With Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
Biomarker Discovery Randomized Phase IIb Trial With Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2024
Intervention Type: Drug
Study Drugs: Carboplatin, Cyclophosphamide, atezolizumab, Paclitaxel
Study Phase: Phase 2
Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer
Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: April 01, 2021
Intervention Type: Drug
Study Drugs: Olaparib, Durvalumab
Study Phase: Phase 2
DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer
DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer
Enrollment Status: Completed
Publish Date: October 24, 2019
Intervention Type: Other
Study Phase: Phase 2/Phase 3
A Multicenter, Open Label Phase I/II Study to Determine the Safety and Immune Modulating Effects of the Therapeutic Human Papilloma Virus 16 (HPV16) E6/E7 Long Peptides Vaccine (ISA101/ISA101b) Immunotherapy in Combination With Standard of Care Therapy (Carboplatin and Paclitaxel With or Without Bevacizumab) in Women With HPV16 Positive Advanced or Recurrent Cervical Cancer Who Have no Curative Treatment Options
A Multicenter, Open Label Phase I/II Study to Determine the Safety and Immune Modulating Effects of the Therapeutic Human Papilloma Virus 16 (HPV16) E6/E7 Long Peptides Vaccine (ISA101/ISA101b) Immunotherapy in Combination With Standard of Care Therapy (Carboplatin and Paclitaxel With or Without Bevacizumab) in Women With HPV16 Positive Advanced or Recurrent Cervical Cancer Who Have no Curative Treatment Options
Enrollment Status: Completed
Publish Date: March 06, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

181 Total Publications

Corrigendum to "Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial" [The Breast 83 (2025) 104547].
Corrigendum to "Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial" [The Breast 83 (2025) 104547].
Journal: Breast (Edinburgh, Scotland)
Published: September 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Kroep's expertise for a condition
ConditionClose
    View All 25 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile